MDM2 and hydrops fetalis: This hierarchical framework provides a mechanistic foundation for rational clinical development strategies, including biomarker-driven patient selection focused on wild-type p53 and MDM2-overexpressing tumors, combination therapeutic approaches pairing HF with DNA-damaging chemotherapeutics or immune checkpoint inhibitors, and mechanism-based dose optimization tailored to specific molecular targets.